Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef proteins of clade B

Vaccine

Volumn 25, Issue 15, 2007, Pages 2863-2885

  Gómez, Carmen Elena ^a   Nájera, Jose Luis ^a   Jiménez, Eva Pérez ^a   Jiménez, Victoria ^a   Wagner, Ralf ^b   Graf, Marcus ^c   Frachette, Marie Joelle ^d   Liljeström, Peter ^e   Pantaleo, Giuseppe ^f   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c Geneart AG   (Germany)

^d SANOFI PASTEUR   (France)

^e KAROLINSKA INSTITUTE   (Sweden)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Clade B vaccine; HIV AIDS; Immune response; Mouse models; MVA; NYVAC; Poxvirus vectors

Indexed keywords

ALPHA INTERFERON; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; INTERLEUKIN 2; NEF PROTEIN; POL PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; ARTICLE; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INDICATION; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC STABILITY; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENIC MOUSE; VIRAL GENETICS; VIRUS ATTENUATION; VIRUS GENE; VIRUS RECOMBINANT; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; ANTIGENS, VIRAL; APOPTOSIS; BASE SEQUENCE; CHICK EMBRYO; FUSION PROTEINS, GAG-POL; GENE PRODUCTS, NEF; GENOMIC INSTABILITY; HELA CELLS; HIV ENVELOPE PROTEIN GP120; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; POXVIRIDAE; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 33947151927     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.09.090     Document Type: Article

References (46)

1. Stover J., Walker N., Garnett G.P., Salomon J.A., Stanecki K.A., Ghys P.D., et al. Can we reverse the HIV/AIDS pandemic with an expanded response?. Lancet 360 9326 (2002) 73-77
2. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 6686 (1998) 648-659
3. Wyatt R., and Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280 5371 (1998) 1884-1888
4. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 5514 (2001) 69-74
5. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 5491 (2000) 486-492
6. Amara R.R., Ibegbu C., Villinger F., Montefiori D.C., Sharma S., Nigam P., et al. Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques. Virology 343 2 (2005) 246-255
7. Zavala F., Rodrigues M., Rodriguez D., Rodriguez J.R., Nussenzweig R.S., and Esteban M. A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells. Virology 280 2 (2001) 155-159
8. Bonnet M.C., Tartaglia J., Verdier F., Kourilsky P., Lindberg A., Klein M., et al. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 74 1 (2000) 11-25
9. Didierlaurent A., Ramirez J.C., Gherardi M., Zimmerli S.C., Graf M., Orbea H.A., et al. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 22 25-26 (2004) 3395-3403
10. Gherardi M.M., Najera J.L., Perez-Jimenez E., Guerra S., Garcia-Sastre A., and Esteban M. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J Virol 77 12 (2003) 7048-7057
11. Gomez C.E., Abaitua F., Rodriguez D., and Esteban M. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma. Virus Res 105 1 (2004) 11-22
12. Webster D.P., Dunachie S., Vuola J.M., Berthoud T., Keating S., Laidlaw S.M., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses [FP9] and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 102 13 (2005) 4836-4841
13. Cox W.I., Tartaglia J., and Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 195 2 (1993) 845-850
14. Hel Z., Tsai W.P., Thornton A., Nacsa J., Giuliani L., Tryniszewska E., et al. Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J Immunol 167 12 (2001) 7180-7191
15. Ramirez J.C., Gherardi M.M., and Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74 2 (2000) 923-933
16. Chakrabarti S., Sisler J.R., and Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23 6 (1997) 1094-1097
17. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., and Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185 12 (1997) 2043-2051
18. Miyahira Y., Murata K., Rodriguez D., Rodriguez J.R., Esteban M., Rodrigues M.M., et al. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 181 1 (1995) 45-54
19. Guerra S., Lopez-Fernandez L.A., Pascual-Montano A., Najera J.L., Zaballos A., and Esteban M. Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells. J Virol 80 2 (2006) 985-998
20. Amara R.R., Villinger F., Staprans S.I., Altman J.D., Montefiori D.C., Kozyr N.L., et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 76 15 (2002) 7625-7631
21. Hanke T., and McMichael A. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol Lett 66 1-3 (1999) 177-181
22. Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., and Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270 5243 (1995) 1811-1815
23. Alfano M., and Poli G. Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol Immunol 42 2 (2005) 161-182
24. Berger E.A., Murphy P.M., and Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17 (1999) 657-700
25. Najera J.L., Gomez C.E., Domingo-Gil E., Gherardi M.M., and Esteban M. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol 80 12 (2006) 6033-6047
26. Blachere N.E., Darnell R.B., and Albert M.L. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol 3 6 (2005) e185
27. Albert M.L. Death-defying immunity: do apoptotic cells influence antigen processing and presentation?. Nat Rev Immunol 4 3 (2004) 223-231
28. Rodriguez F., Harkins S., Slifka M.K., and Whitton J.L. Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J Virol 76 9 (2002) 4251-4259
29. Palmowski M.J., Choi E.M., Hermans I.F., Gilbert S.C., Chen J.L., Gileadi U., et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168 9 (2002) 4391-4398
30. Liu F., Whitton J.L., and Slifka M.K. The rapidity with which virus-specific CD8+ T cells initiate IFN-gamma synthesis increases markedly over the course of infection and correlates with immunodominance. J Immunol 173 1 (2004) 456-462
31. Draenert R., Brander C., Yu X.G., Altfeld M., Verrill C.L., Feeney M.E., et al. Impact of intrapeptide epitope location on CD8 T cell recognition: implications for design of overlapping peptide panels. AIDS 18 6 (2004) 871-876
32. Barouch D.H., Kunstman J., Kuroda M.J., Schmitz J.E., Santra S., Peyerl F.W., et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415 6869 (2002) 335-339
33. Pantaleo G., Menzo S., Vaccarezza M., Graziosi C., Cohen O.J., Demarest J.F., et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 332 4 (1995) 209-216
34. Gea-Banacloche J.C., Migueles S.A., Martino L., Shupert W.L., McNeil A.C., Sabbaghian M.S., et al. Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol 165 2 (2000) 1082-1092
35. Graham B.S. Clinical trials of HIV vaccines. Annu Rev Med 53 (2002) 207-221
36. Iqbal S.M., Ball T.B., Kimani J., Kiama P., Thottingal P., Embree J.E., et al. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis 192 5 (2005) 728-738
37. Antoine G., Scheiflinger F., Dorner F., and Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244 2 (1998) 365-396
38. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188 1 (1992) 217-232
39. Tscharke D.C., Karupiah G., Zhou J., Palmore T., Irvine K.R., Haeryfar S.M., et al. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 201 1 (2005) 95-104
40. Oseroff C., Kos F., Bui H.H., Peters B., Pasquetto V., Glenn J., et al. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci USA 102 39 (2005) 13980-13985
41. Anderson R.J., Hannan C.M., Gilbert S.C., Laidlaw S.M., Sheu E.G., Korten S., et al. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J Immunol 172 5 (2004) 3094-3100
42. Bruna-Romero O., Gonzalez-Aseguinolaza G., Hafalla J.C., Tsuji M., and Nussenzweig R.S. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci USA 98 20 (2001) 11491-11496
43. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78 8 (2004) 3930-3940
44. Benson J., Chougnet C., Robert-Guroff M., Montefiori D., Markham P., Shearer G., et al. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol 72 5 (1998) 4170-4182
45. Nilsson C., Makitalo B., Berglund P., Bex F., Liljestrom P., Sutter G., et al. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 19 25-26 (2001) 3526-3536
46. Vuola J.M., Keating S., Webster D.P., Berthoud T., Dunachie S., Gilbert S.C., et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 174 1 (2005) 449-455